| 2025-12-03 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies' Noninvasive CyPath(TM) Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable |
| 2025-11-14 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Reports Third Quarter 2025 Financial Results |
| 2025-10-28 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases |
| 2025-10-20 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Presents Research Supporting CyPath(TM) Lung Processing Methods at CHEST 2025 |
| 2025-10-16 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer |
| 2025-10-15 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements |
| 2025-10-09 14:00 | UU:BIAF | | News Release200 | WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules |
| 2025-10-09 13:00 | UU:BIAF | | News Release200 | bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules |
| 2025-10-08 16:15 | UU:BIAF | | News Release200 | WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules |
| 2025-10-08 15:45 | UU:BIAF | | News Release200 | bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules |
| 2025-10-07 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Reports Record Growth in CyPath(TM) Lung Test Volume for Third Quarter 2025 |
| 2025-09-30 12:30 | UU:BIAF | | News Release200 | WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m |
| 2025-09-30 12:15 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Closing of $4.8 Million Public Offering |
| 2025-09-29 17:59 | UU:BIAF | | News Release200 | WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m |
| 2025-09-29 15:51 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering |
| 2025-09-26 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath(TM) Lung |
| 2025-09-17 08:15 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 |
| 2025-09-09 08:00 | UU:BIAF | | News Release200 | Case Study: CyPath(TM) Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules |
| 2025-09-03 08:00 | UU:BIAF | | News Release200 | U.S. Medicine Magazine Spotlights CyPath(TM) Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA |
| 2025-08-18 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Appoints New Members to Board of Directors |
| 2025-08-14 16:15 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds |
| 2025-08-14 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Reports Second Quarter 2025 Results |
| 2025-08-13 10:15 | UU:BIAF | | News Release200 | WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds |
| 2025-08-13 09:25 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds |
| 2025-08-13 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Reports Accelerating Growth in CyPath(TM) Lung Test Sales |
| 2025-07-29 08:00 | UU:BIAF | | News Release200 | Case Study: CyPath(TM) Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results |
| 2025-07-23 08:00 | UU:BIAF | | News Release200 | Case Study: CyPath(TM) Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools |
| 2025-07-22 09:00 | UU:BIAF | | News Release200 | Canada Awards New Patent to bioAffinity Technologies for CyPath(TM) Lung, Company's Noninvasive Lung Cancer Diagnostic |
| 2025-07-15 09:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic |
| 2025-07-09 09:00 | UU:BIAF | | News Release200 | Case Study: CyPath(TM) Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging |
| 2025-06-26 09:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference |
| 2025-06-24 09:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy |
| 2025-06-11 09:00 | UU:BIAF | | News Release200 | bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board |
| 2025-06-03 09:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Works With Cardinal Health(TM) OptiFreight(TM) Logistics to Help Meet Demand for CyPath(TM) Lung |
| 2025-05-28 09:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics |
| 2025-05-20 09:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer |
| 2025-05-15 08:30 | UU:BIAF | | News Release200 | bioAffinity Technologies Reports First Quarter 2025 Results |
| 2025-05-08 09:00 | UU:BIAF | | News Release200 | Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath(TM) Lung in Diagnosing Early-Stage Lung Cancer |
| 2025-05-07 13:15 | UU:BIAF | | News Release200 | WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering |
| 2025-05-07 13:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Closing of $3.25 Million Offering |
| 2025-05-06 10:30 | UU:BIAF | | News Release200 | WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering |
| 2025-05-06 09:25 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Pricing of $3.25 Million Offering |
| 2025-04-17 09:15 | UU:BIAF | | News Release200 | bioAffinity Technologies Increases Efficiency of CyPath(TM) Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost |
| 2025-03-31 09:28 | UU:BIAF | | News Release200 | bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 |
| 2025-03-26 09:00 | UU:BIAF | | News Release200 | Case Study: bioAffinity Technologies' CyPath(TM) Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer |
| 2025-03-19 09:00 | UU:BIAF | | News Release200 | Case Study: bioAffinity Technologies' Positive CyPath(TM) Lung Result Leads to Detecting Breast Cancer Recurrence |
| 2025-03-13 09:00 | UU:BIAF | | News Release200 | Physicians' Case Studies Offer Insight into Use and Benefit of CyPath(TM) Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer |
| 2025-03-06 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath(TM) Lung Sales Growth |
| 2025-02-26 12:10 | UU:BIAF | | News Release200 | WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million |
| 2025-02-26 11:30 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million |
| 2025-02-25 11:05 | UU:BIAF | | News Release200 | WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million |
| 2025-02-25 09:58 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million |
| 2025-01-30 09:00 | UU:BIAF | | News Release200 | Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029 |
| 2025-01-22 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic |
| 2025-01-13 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath(TM) Lung |
| 2025-01-10 09:02 | UU:BIAF | | News Release200 | Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV |
| 2024-12-17 08:00 | UU:BIAF | | News Release200 | Join bioAffinity Technologies' Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19 |
| 2024-12-12 08:00 | UU:BIAF | | News Release200 | bioAffinity Technologies Set for Continued Expansion in 2025 |